Amazon Pharmacy to Deliver GLP-1 Weight-Loss Drugs to Medicare Beneficiaries at $50 Monthly Copay

Amazon Pharmacy said Wednesday that it is now delivering certain GLP-1 weight-loss drugs to eligible Medicare beneficiaries for a $50 monthly copay through the federal Medicare GLP-1 Bridge program, linking its home-delivery network to a new government effort to expand access to the high-cost medicines.

In its announcement, Amazon said the covered drugs include Wegovy, in injectable and oral tablet forms, Zepbound KwikPen and Foundayo. The company said patients can add their Bridge insurance plan and Medicare ID to their Amazon Pharmacy account, and that it “automates eligibility verification, prior authorization, and billing.” Amazon is also emphasizing free home delivery nationwide, same-day delivery in more than 3,100 U.S. cities and towns, no Prime membership requirement, and pickup at Amazon Pharmacy kiosks in select One Medical locations. It said same-day delivery is expected to reach nearly 4,500 cities and towns by the end of 2026.

The $50 monthly copay is set by the Centers for Medicare and Medicaid Services, not Amazon. CMS, the federal agency that runs Medicare, said the Medicare GLP-1 Bridge program launched July 1, 2026, and will run through Dec. 31, 2027. The temporary demonstration gives eligible Medicare Part D beneficiaries access to certain GLP-1 drugs for weight management at $50 a month while the agency gathers data and develops longer-term payment models.

Eligibility is limited. CMS says the program is for beneficiaries who meet clinical and plan criteria and who are prescribed one of the covered drugs specifically to reduce excess body weight or maintain weight reduction. People who already receive GLP-1 drugs through Part D, or who are using them for Type 2 diabetes, moderate-to-severe obstructive sleep apnea or certain fatty-liver indications, are not eligible for the Bridge program.

Amazon’s pitch is that it can make a complicated benefit easier to use, not that it changes the federal rules. CMS still requires prior authorization and prescriber attestation for Bridge coverage. Amazon says it streamlines that process by handling eligibility checks, paperwork and billing through its pharmacy platform. “We want to make sure nothing stands in the way—no confusing paperwork, no prior authorization delays, no waiting at a pharmacy counter,” Tanvi Patel, vice president and general manager of Amazon Pharmacy, said in the company’s announcement.

CMS has framed the Bridge as a way to lower a major cost barrier for patients who qualify. “For too long, many Americans have been unable to access these treatments because of cost,” CMS Administrator Dr. Mehmet Oz said when the agency announced the program. “The Medicare GLP-1 Bridge creates a new pathway for eligible beneficiaries to afford GLP-1 medications.”

The program is national and can be used by pharmacies broadly, but Amazon is trying to stand out by combining the federal subsidy with fast delivery, paperwork support and clinic-based kiosk pickup through its expanding health care business, which includes Amazon Pharmacy and One Medical. One practical limitation for beneficiaries: CMS says Bridge claims are processed outside the normal Part D payment flow, so the $50 copay does not count toward a patient’s Part D out-of-pocket spending thresholds.